AstraZeneca Pharma India Ltd receives permission from DCGI for Dapagliflozin Tablets 10 mg

AstraZeneca Pharma India Limited has received Permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation - Additional Indication) from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.

Through this approval, Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults.

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 3769.40 as compared to the previous close of Rs. 3802.25. The total number of shares traded during the day was 536 in over 260 trades.

The stock hit an intraday high of Rs. 3805.05 and intraday low of 3752.75. The net turnover during the day was Rs. 2026531.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 DCGI NewDrug Sale Distribution DapagliflozinTablets